CYDX (Cyduct Diagnostics) EBIT: $ Mil (TTM As of . 20)


What is Cyduct Diagnostics EBIT?

Cyduct Diagnostics CYDX +4.22% EBIT is $ Mil as of . 20.

Cyduct Diagnostics's earnings before interest and taxes (EBIT) for the three months ended in . 20 was $0.00 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Cyduct Diagnostics  (OTCPK:CYDX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cyduct Diagnostics's annualized ROC % for the quarter that ended in . 20 is calculated as:

ROC % (Q: . 20 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: . 20 ) + Invested Capital (Q: . 20 ))/ count )
= * ( 1 - % )/( ( + )/ )
=/
= %

where

Invested Capital(Q: . 20 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
= - - ( - max(0, - +))
=

Invested Capital(Q: . 20 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
= - - ( - max(0, - +))
=

Note: The Operating Income data used here is four times the quarterly (. 20) data.

2. Joel Greenblatt's definition of Return on Capital:

Cyduct Diagnostics's annualized ROC (Joel Greenblatt) % for the quarter that ended in . 20 is calculated as:

ROC (Joel Greenblatt) %(Q: . 20 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: . 20  Q: . 20
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=/( ( ( + max(, 0)) + ( + max(, 0)) )/ )
=/( ( + )/ )
=/
= %

where Working Capital is:

Working Capital(Q: . 20 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=( + + ) - ( + + )
=

Working Capital(Q: . 20 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=( + + ) - ( + + )
=

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (. 20) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Cyduct Diagnostics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: . 20 )
=/2.201
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyduct Diagnostics EBIT Related Terms

Cyduct Diagnostics EBIT Historical Data

* Premium members only.

The historical data trend for Cyduct Diagnostics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyduct Diagnostics EBIT Chart

Cyduct Diagnostics Annual Data
Trend
EBIT

Cyduct Diagnostics Quarterly Data
EBIT

CYDX vs SECI, QTXB, ASNB: EBIT Comparison

For the Medical Devices subindustry, Cyduct Diagnostics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyduct Diagnostics EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cyduct Diagnostics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cyduct Diagnostics's EV-to-EBIT falls into.


Cyduct Diagnostics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in . 20 adds up the quarterly data reported by the company within the most recent 12 months, which was $ Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $ Mil mean?
Cyduct Diagnostics (CYDX) has a EBIT of $ Mil as of . 20. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Cyduct Diagnostics.
Is Cyduct Diagnostics' EBIT too high?
Cyduct Diagnostics' current EBIT is $ Mil.
How does Cyduct Diagnostics' EBIT compare to SECI and QTXB?
Cyduct Diagnostics' EBIT of $ Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Cyduct Diagnostics. Cyduct Diagnostics's current EBIT is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyduct Diagnostics stock overvalued right now?
Cyduct Diagnostics (CYDX) has a current EBIT of $ Mil. The current EBIT is $ Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Cyduct Diagnostics (CYDX), the current EBIT is $ Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cyduct Diagnostics Business Description

Address 1698 Post Road East, Suite 1A, Westport, CT, USA, 06880
Cyduct Diagnostics Inc is a clinical-stage diagnostic company. It focuses on creating and enhancing a portfolio of technologies and assets based on the early assessment and detection of Breast Cancer. Its technology platform of MammoView devices is a single-use, high-margin product that assesses, screens, detects, monitors, and facilitates the treatment of identifiable changes that distinguish variations in breast health. The company markets these products under its Solos Endoscopy brand, along with a line of branded surgical instruments, manufactured by third parties to its design specifications, mainly endoscopes and hand-held surgical instruments for the minimally invasive surgery market.